Clinical significance of T-cadherin tissue expression in patients with bladder transitional cell carcinoma

Urologia Internationalis

Volumn 86, Issue 3, 2011, Pages 340-345

  Lin, Yingli ^a,b   Sun, Guang ^a,b   Liu, Xiaoqiang ^a,b   Chen, Yegang ^a,b   Zhang, Chunting ^a,b  

^a Medical University   (China)

^b Tianjin Institute of Urological Surgery   (China)

Author keywords

Bladder cancer; T cadherin; Transitional cell carcinoma

Indexed keywords

CADHERIN; T CADHERIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER RELAPSE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

AGED; CADHERINS; CARCINOMA, TRANSITIONAL CELL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 79955101944     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322962     Document Type: Article

References (27)

1. Van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR: Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009; 56: 430-3442.
2. Ploeg M, Aben KK, Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol 2009; 27: 289-293.
3. Jacobs BL, Lee CT, Montie JE: Bladder cancer in 2010: how far have we come? CA Cancer J Clin 2010; 60: 244-272.
4. Rouprêt M, Hupertan V, Yates DR, Comperat E, Catto JW, Meuth M, Lackmichi A, Ricci S, Lacave R, Gattegno B, Richard F, Hamdy FC, Cussenot O: A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int 2008; 101: 1448-1453. (Pubitemid 351623989)
5. Bolenz C, Lotan Y: Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. Nat Clin Pract Urol 2008; 5: 676-685.
6. Vrooman OP, Witjes JA: Molecular markers for detection, surveillance and prognostication of bladder cancer. Int J Urol 2009; 16: 234-243.
7. Andreeva AV, Kutuzov MA: Cadherin-13 in cancer. Genes Chromosomes Cancer 2010; 49: 775-790.
8. Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, Ito T, Hamilton JP, David S, Agarwal R, Selaru FM, Sato F, Abraham JM, Beer DG, Mori Y, Shimada Y, Meltzer SJ: Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer 2008; 123: 2331-2336.
9. Kim DS, Kim MJ, Lee JY, Kim YZ, Kim EJ, Park JY: Aberrant methylation of E-cadherin and H-cadherin genes in non-small cell lung cancer and its relation to clinicopathologic features. Cancer 2007; 110: 2785-2792.
10. Lee SW: H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. Nat Med 1996; 2: 776-782. (Pubitemid 26225093)
11. Mukoyama Y, Zhou S, Miyachi Y, Matsuyoshi N: T-cadherin negatively regulates the proliferation of cutaneous squamous carcinoma cells. J Invest Dermatol 2005; 124: 833-838. (Pubitemid 40489512)
12. Yan Q, Zhang ZF, Chen XP, Gutmann DH, Xiong M, Xiao ZY, Huang ZY: Reduced Tcadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma. Int J Oncol 2008; 32: 1057-1063.
13. Kuphal S, Martyn AC, Pedley J, Crowther LM, Bonazzi VF, Parsons PG, Bosserhoff AK, Hayward NK, Boyle GM: H-cadherin expression reduces invasion of malignant melanoma. Pigment Cell Melanoma Res 2009; 22: 296-306.
14. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF: Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001; 61: 8659-8663. (Pubitemid 34013873)
15. Yu J, Zhu T, Wang Z, Zhang H, Qian Z, Xu H, Gao B, Wang W, Gu L, Meng J, Wang J, Feng X, Li Y, Yao X, Zhu J: A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 2007; 13: 7296-7304.
16. Mostofi FK, Sobin LH, Torloni H: Histological Typing of Urinary Bladder Tumors. International Histological Classification of Tumors, No. 10. Geneva, WHO, 1973.
17. Sobin LH, Wittekind C: TNM Classification of Malignant Tumours. International Union Against Cancer (UICC), ed 6. New York, Wiley-Liss, 2002.
18. Kim JS, Han J, Shim YM, Park J, Kim DH: Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary non-small cell lung carcinoma. Cancer 2005; 104: 1825-1833. (Pubitemid 41513164)
19. Shi B, Laudon V, Yu S, Dong D, Zhu Y, Xu Z: E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. Urol Int 2008; 81: 320-324.
20. Widschwendter A, Ivarsson L, Blassnig A, Müller HM, Fiegl H, Wiedemair A, Müller- Holzner E, Goebel G, Marth C, Widschwendter M: CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer 2004; 109: 163-166. (Pubitemid 38240915)
21. Adachi Y, Takeuchi T, Nagayama T, Furihata M: T-cadherin modulates tumor-associated molecules in gallbladder cancer cells. Cancer Invest 2010; 28: 120-126.
22. Qian ZR, Sano T, Yoshimoto K, Asa SL, Yamada S, Mizusawa N, Kudo E: Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol 2007; 20: 1269-1277. (Pubitemid 350126852)
23. Hibi K, Nakayama H, Kodera Y, Ito K, Akiyama S, Nakao A: CDH13 promoter region is specifically methylated in poorly differentiated colorectal cancer. Br J Cancer 2004; 90: 1030-1033. (Pubitemid 38495824)
24. Kaufman DS, Shipley WU, Feldman AS: Bladder cancer. Lancet 2009; 374: 239-249.
25. Huang ZY, Wu Y, Hedrick N, Gutmann DH: T-cadherin-mediated cell growth regulation involves G2 phase arrest and requires p21(CIP1/WAF1) expression. Mol Cell Biol 2003; 23: 566-578. (Pubitemid 36050550)
26. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG: DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008; 358: 1118-1128. (Pubitemid 351398486)
27. Lopez-Beltran A: Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol Suppl 2008; 218: 95-109.